Proteomic characterization of Her2/neu-overexpressing breast cancer cells

Proteomics

Volumn 10, Issue 21, 2010, Pages 3800-3810

  Chen, Hexin ^a   Pimienta, Genaro ^b   Gu, Yiben ^a   Sun, Xu ^c,d   Hu, Jianjun ^c,d   Kim, Min Sik ^b   Chaerkady, Raghothama ^b,f   Gucek, Marjan ^b   Cole, Robert N ^b   Sukumar, Saraswati ^e   Pandey, Akhilesh ^b,c,g  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d University of South Carolina   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f Institute of Bioinformatics   (India)

^g YALE UNIVERSITY   (United States)

Author keywords

Biomedicine; Cancer biomarker; Her2; Quantitative proteomics SILAC

Indexed keywords

CELLULAR RETINOL BINDING PROTEIN 1; CREATINE KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELSOLIN; THROMBOSPONDIN 1; THYMOSIN; THYMOSIN 4; TUMOR PROTEIN; TUMOR PROTEIN D52; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENICITY; COMPUTER MODEL; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; DISEASE FREE SURVIVAL; DOWN REGULATION; EPITHELIUM CELL; FEMALE; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEOMICS; UPREGULATION;

ANIMALS; CELL COUNT; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COMPUTER SIMULATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PROTEOMICS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

MOUSE MAMMARY TUMOR VIRUS; MUS MUSCULUS;

EID: 78049413408     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000297     Document Type: Article

References (46)

1. Hanahan, D., Weinberg, R. A., The hallmarks of cancer. Cell 2000, 100, 57-70.
2. Citri, A., Yarden, Y., EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell. Biol. 2006, 7, 505-516.
3. Hondermarck, H., Breast cancer: when proteomics challenges biological complexity. Mol. Cell. Proteomics 2003, 2, 281-291.
4. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T. et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98, 10869-10874.
5. Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M. et al., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421, 756-760.
6. Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C. et al., The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 2003, 11, 495-505.
7. Kim, I. Y., Yong, H. Y., Kang, K. W., Moon, A., Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9. Cancer Lett. 2009, 275, 227-233.
8. Korkaya, H., Paulson, A., Iovino, F., Wicha, M. S., HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27, 6120-6130.
9. Bertucci, F., Finetti, P., Cervera, N., Esterni, B. et al., How basal are triple-negative breast cancers? Int. J. Cancer 2008, 123, 236-240.
10. Hegde, P. S., Rusnak, D., Bertiaux, M., Alligood, K. et al., Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol. Cancer Ther. 2007, 6, 1629-1640.
11. Huang, H., Groth, J., Sossey-Alaoui, K., Hawthorn, L. et al., Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin. Cancer Res. 2005, 11, 4357-4364.
12. Wilson, K. S., Roberts, H., Leek, R., Harris, A. L., Geradts, J., Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am. J. Pathol. 2002, 161, 1171-1185.
13. Rauser, S., Marquardt, C., Balluff, B., Deininger, S. O. et al., Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J. Proteome Res. 9, 1854-1863.
14. Somiari, R. I., Sullivan, A., Russell, S., Somiari, S. et al., High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 2003, 3, 1863-1873.
15. Huang, H. L., Stasyk, T., Morandell, S., Dieplinger, H. et al., Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/ MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 2006, 27, 1641-1650.
16. Toillon, R. A., Lagadec, C., Page, A., Chopin, V. et al., Proteomics demonstration that normal breast epithelial cells can induce apoptosis of breast cancer cells through insulin-like growth factor-binding protein-3 and maspin. Mol. Cell. Proteomics 2007, 6, 1239-1247.
17. Whiteaker, J. R., Zhang, H., Zhao, L., Wang, P. et al., Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J. Proteome Res. 2007, 6, 3962-3975.
18. Menon, R., Omenn, G. S., Proteomic characterization of novel alternative splice variant proteins in human epidermal growth factor receptor 2/neu-induced breast cancers. Cancer Res. 70, 3440-3449.
19. Schulz, D. M., Bollner, C., Thomas, G., Atkinson, M. et al., Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J. Proteome Res. 2009, 8, 3430-3438.
20. Adam, P. J., Boyd, R., Tyson, K. L., Fletcher, G. C. et al., Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J. Biol. Chem. 2003, 278, 6482-6489.
21. Chan, H. L., Gharbi, S., Gaffney, P. R., Cramer, R. et al., Proteomic analysis of redox- and ErbB2-dependent changes in mammary luminal epithelial cells using cysteine- and lysine-labelling two-dimensional difference gel electrophoresis. Proteomics 2005, 5, 2908-2926.
22. Li, D. Q., Wang, L., Fei, F., Hou, Y. F. et al., Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 2006, 6, 3352-3368.
23. Malorni, L., Cacace, G., Cuccurullo, M., Pocsfalvi, G. et al., Proteomic analysis of MCF-7 breast cancer cell line exposed to mitogenic concentration of 17beta-estradiol. Proteomics 2006, 6, 5973-5982.
24. Ou, K., Yu, K., Kesuma, D., Hooi, M. et al., Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping. J. Proteome Res. 2008, 7, 1518-1528.
25. Sarvaiya, H. A., Yoon, J. H., Lazar, I. M., Proteome profile of the MCF7 cancer cell line: a mass spectrometric evaluation. Rapid Commun. Mass Spectrom. 2006, 20, 3039-3055.
26. Zhang, D., Tai, L. K., Wong, L. L., Chiu, L. L. et al., Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell Proteomics 2005, 4, 1686-1696.
27. Chen, H., Lee, J. S., Liang, X., Zhang, H. et al., Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis. Cancer Res. 2008, 68, 3637-3644.
28. Harsha, H. C., Molina, H., Pandey, A., Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nat. Protoc. 2008, 3, 505-516.
29. Chaerkady, R., Harsha, H. C., Nalli, A., Gucek, M. et al., A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J. Proteome Res. 2008, 7, 4289-4298.
30. Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M. et al., Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365, 671-679.
31. van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H. et al., A gene-expression signature as a predictor of survival in breast cancer. New England J. Med. 2002, 347, 1999-2009.
32. Bair, E., Hastie, T., Paul, T., Tibshirani, R., Prediction by supervised principal components. J Am. Stat. Assoc. 2006, 101, 119-137.
33. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J. et al., Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 1992, 89, 10578-10582.
34. Huff, T., Rosorius, O., Otto, A. M., Muller, C. S. et al., Nuclear localisation of the G-actin sequestering peptide thymosin beta4. J. Cell Sci. 2004, 117, 5333-5341.
35. Philp, D., Huff, T., Gho, Y. S., Hannappel, E., Kleinman, H. K., The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003, 17, 2103-2105.
36. Bergers, G., Benjamin, L. E., Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3, 401-410.
37. Wen, X. F., Yang, G., Mao, W., Thornton, A. et al., HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006, 25, 6986-6996.
38. Walsh, N., Dowling, P., O'Donovan, N., Henry, M. et al., Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells. J. Proteomics 2008, 71, 561-571.
39. Thor, A. D., Edgerton, S. M., Liu, S., Moore, D. H., 2nd, Kwiatkowski, D. J., Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin. Cancer Res. 2001, 7, 2415-2424.
40. Orlandi, A., Ferlosio, A., Ciucci, A., Francesconi, A. et al., Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications. Mod. Pathol. 2006, 19, 797-803.
41. Schmitt-Graeff, A., Koeninger, A., Olschewski, M., Haxelmans, S. et al., The Ki67+ proliferation index correlates with increased cellular retinol-binding protein-1 and the coordinated loss of plakophilin-1 and desmoplakin during progression of cervical squamous lesions. Histopathology 2007, 51, 87-97.
42. Tagliabue, E., Balsari, A., Campiglio, M., Pupa, S. M., HER2 as a target for breast cancer therapy. Expert Opin. Biol. Ther. 10, 711-724.
43. Landis, M. D., Seachrist, D. D., Montanez-Wiscovich, M. E., Danielpour, D., Keri, R. A., Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene 2005, 24, 5173-5190.
44. Astolfi, A., Landuzzi, L., Nicoletti, G., De Giovanni, C. et al., Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am. J. Pathol. 2005, 166, 1205-1216.
45. Solassol, J., Jacot, W., Lhermitte, L., Boulle, N. et al., Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev. Proteomics 2006, 3, 311-320.
46. Sigdel, T. K., Sarwal, M. M., The proteogenomic path towards biomarker discovery. Pediatr. Transplant. 2008, 12, 737-747.